Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae451 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Stephanie L Rolsma und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Cystic Fibrosis, Meropenem, Cefepime, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, NIH HHS.
Abstract (Originalsprache)
Background
Patients with cystic fibrosis (CF) experience recurrent bacterial pulmonary exacerbations. Management of these infections is increasingly challenging due to decreased antimicrobial susceptibility to β-lactam antibiotics. The pharmacokinetics (PK) of these agents are inadequately characterized in patients with CF.
Methods
This study enrolled 155 pediatric and adult participants with CF who were receiving the following β-lactam antibiotics: cefepime (n = 82), meropenem (n = 42), or piperacillin-tazobactam (n = 31). Opportunistic blood samples were obtained during hospitalization. Population PK analysis was conducted via nonlinear mixed effects modeling. Clinical and demographic characteristics were evaluated as potential covariates. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA) for different dosing regimens.
Results
Estimated creatinine clearance and total or lean body weight affected the PK of cefepime and meropenem. No covariates were identified for piperacillin and tazobactam. In the cefepime group, a 3-hour infusion achieved a higher PTA than a 0.5-hour infusion for all participants. Estimated breakpoints—the respective minimum inhibitory concentration up to which ≥90% of patients are predicted to reach a PK/pharmacodynamic target—were 2- to 4-fold higher in pediatric participants receiving a 3- vs 0.5-hour infusion. In the meropenem group, increased creatinine clearance led to reduced PTA. In the piperacillin-tazobactam group, total daily dose and mode of administration were principal drivers of PTA.
Conclusions
Standard dosing regimens fail to achieve specific minimum inhibitory concentration targets in patients with CF. Therefore, clinicians should incorporate local antibiograms and PK models to determine optimal dosing. Further PK optimization to account for interindividual differences could be achieved by real-time β-lactam therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
- Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
- Division of Pediatric Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
ORCID-Profile: Stephanie L Rolsma, Andrew Sokolow, Pratish C Patel, Natalia Jimenez-Truque, William H Fissell, Carl M Kirkpatrick, Roger L Nation, Kenan Gu, Guohua An, Patricia Winokur, Cornelia B Landersdorfer, C Buddy Creech
Förderung
- NIAID NIH HHS
- Division of Microbiology and Infectious Diseases
- NIH HHS
- National Institutes of Health
Zitieren
APA
Rolsma, S. L., Sokolow, A., Patel, P. C., Sokolow, K., Jimenez-Truque, N., Fissell, W. H., Ryan, V., Kirkpatrick, C. M., Nation, R. L., Gu, K., Teresi, M., Fishbane, N., Kontos, M., An, G., Winokur, P., Landersdorfer, C. B., & Creech, C. B. (2025). Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae451
Vancouver
Rolsma SL, Sokolow A, Patel PC, Sokolow K, Jimenez-Truque N, Fissell WH, et al. Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae451
BibTeX
@article{Rolsma2025,
author = {Rolsma, Stephanie L and Sokolow, Andrew and Patel, Pratish C and Sokolow, Katherine and Jimenez-Truque, Natalia and Fissell, William H and Ryan, Vivian and Kirkpatrick, Carl M and Nation, Roger L and Gu, Kenan and Teresi, Mary and Fishbane, Nicholas and Kontos, Marissa and An, Guohua and Winokur, Patricia and Landersdorfer, Cornelia B and Creech, C Buddy},
title = {Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae451}
}
EUVIMED